Hai cercato: Thymine

Fornitore: TCI EUROPE

Descrizione: Thymine ≥98.0% (by HPLC, titration analysis)

Fornitore: Thermo Scientific

Descrizione: Thymine 99%

MSDS

Codice catalogo: (APOSBIMN2031-1G)

Fornitore: Apollo Scientific

Codice articolo fornitore: BIMN2031-1G

Codice articolo locale: APOSBIMN2031-1G

Descrizione: 1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (2’-FANA-T) ≥95%

UOM: 1 * 1 g

Promo

Fornitore: Thermo Scientific

Descrizione: Thymine 97%

MSDS Certificati

Codice catalogo: (PHR1345-250MG)

Fornitore: Merck

Codice articolo fornitore: PHR1345-250MG

Codice articolo locale: SUPLPHR1345-250MG

Descrizione: Organic Standard, Thymine(Zidovudine Related Compound C)

UOM: 1 * 250 mg

Promo

Codice catalogo: (TCIAA2073-25G)

Fornitore: TCI EUROPE

Codice articolo fornitore: A2073-25G

Codice articolo locale: TCIAA2073-25G

Descrizione: 1-(3,5-Anhydro-2-deoxy-β-D-threo-pentofuranosyl)thymine ≥98.0% (by HPLC, titration analysis)

UOM: 1 * 25 g

Promo

Fornitore: TCI EUROPE

Descrizione: Timidina (2'-Deossitimidina) ≥98.0% (by HPLC, titration analysis)

Codice catalogo: (BOSSBS-8288R)

Fornitore: Bioss

Codice articolo fornitore: BS-8288R

Codice articolo locale: BOSSBS-8288R

Descrizione: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-2950R-CY7)

Fornitore: Bioss

Codice articolo fornitore: BS-2950R-CY7

Codice articolo locale: BOSSBS-2950R-CY7

Descrizione: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-2950R-CY5)

Fornitore: Bioss

Codice articolo fornitore: BS-2950R-CY5

Codice articolo locale: BOSSBS-2950R-CY5

Descrizione: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-8288R-CY5)

Fornitore: Bioss

Codice articolo fornitore: BS-8288R-CY5

Codice articolo locale: BOSSBS-8288R-CY5

Descrizione: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-8288R-CY3)

Fornitore: Bioss

Codice articolo fornitore: BS-8288R-CY3

Codice articolo locale: BOSSBS-8288R-CY3

Descrizione: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-8288R-A350)

Fornitore: Bioss

Codice articolo fornitore: BS-8288R-A350

Codice articolo locale: BOSSBS-8288R-A350

Descrizione: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-2950R-A750)

Fornitore: Bioss

Codice articolo fornitore: BS-2950R-A750

Codice articolo locale: BOSSBS-2950R-A750

Descrizione: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-8288R-FITC)

Fornitore: Bioss

Codice articolo fornitore: BS-8288R-FITC

Codice articolo locale: BOSSBS-8288R-FITC

Descrizione: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Promo

Codice catalogo: (BOSSBS-8288R-A680)

Fornitore: Bioss

Codice articolo fornitore: BS-8288R-A680

Codice articolo locale: BOSSBS-8288R-A680

Descrizione: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterised by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Promo